{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-122267","form_type":"8-K","ticker":"RBOT","cik":"0001812173","company_name":"Vicarious Surgical Inc.","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.549494+00:00","generated_at":"2026-05-16T13:05:15.594904+00:00","sec_items":["1.01","3.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vicarious Surgical guides FY2026 cash burn ~$35M (improved from $45M); NYSE to delist warrants","bullets":["FY2026 cash burn guidance of ~$35M, a $10M improvement over the recently updated $45M 2025 guidance.","Additional cash needs beyond existing resources to achieve design freeze on Vicarious Surgical system are ~$25M.","Design freeze targeted by year-end 2026; cost reductions from headcount and consulting partially offset by strategic outsourcing.","NYSE to delist and immediately suspend trading in the Company's warrants (RBOT.WS) due to abnormally low price levels. No appeal.","Entered into ATM agreement with H.C. Wainwright for potential sale of up to ~$2.3M of common stock (based on Form S-3 limitation); 3% commission."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-122267","json":"https://secwatch.observer/filing/0001213900-25-122267.json","markdown":"https://secwatch.observer/filing/0001213900-25-122267.md","text":"https://secwatch.observer/filing/0001213900-25-122267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/ea0269650-8k_vicarious.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:05:15.594904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ac5563b2bc5d7d7e2020bf5a8971b122472f637","claim":"Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).","evidence_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026, and continued compliance with the NYSE’s other continued listing requirements.","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","confidence":0.7},{"claim_id":"5f563bb55e46331bcd71ba559cb5e97e6385b73a","claim":"Vicarious Surgical Inc. received a nyse delisting notice notice regarding other (rules 802.01D).","evidence_excerpt":"December 15, 2025, the NYSE notified the Company that the NYSE has determined to (a) commence proceedings to delist the Company’s warrants, with thirty warrants exercisable for one share of Common Stock, at an exercise price of $345.00 per share, and listed to trade on the NYSE under the symbol “RBOT.WS” (the “Public Warrants”) and (b) immediately suspend trading in the Public Warrants due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Common Stock w","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-055912","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-05-13T21:00:25+00:00","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","event_type":"other_material","sec_items":["1.01","3.01","3.02","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055912","json":"https://secwatch.observer/filing/0001213900-26-055912.json","markdown":"https://secwatch.observer/filing/0001213900-26-055912.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea0290143-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will\nbe unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock\nremains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of\nthe NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,\nand continued compliance with the NYSE’s other continued listing requirements.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","comparable_excerpt":"minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum\nBid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm"}},{"accession":"0001493152-26-019078","ticker":"GNLN","company_name":"Greenlane Holdings, Inc.","filed_at":"2026-04-27T23:59:59+00:00","headline":"Greenlane regains Nasdaq compliance; BIC limits warrant conversion; board lock-up to April 2027","event_type":"other_material","sec_items":["3.01","7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-019078","json":"https://secwatch.observer/filing/0001493152-26-019078.json","markdown":"https://secwatch.observer/filing/0001493152-26-019078.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743745/000149315226019078/0001493152-26-019078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743745/000149315226019078/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will\nbe unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock\nremains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of\nthe NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,\nand continued compliance with the NYSE’s other continued listing requirements.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","comparable_excerpt":"March 25, 2026, Greenlane Holdings, Inc. (the “ Company ”) received a written notice\n(the “ Notice ”) from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”)\nindicating that Nasdaq s","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1743745/000149315226019078/0001493152-26-019078-index.htm"}},{"accession":"0001213900-26-060267","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-22T01:40:52+00:00","headline":"AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060267","json":"https://secwatch.observer/filing/0001213900-26-060267.json","markdown":"https://secwatch.observer/filing/0001213900-26-060267.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/ea0291955-8k_allinfuture.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will\nbe unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock\nremains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of\nthe NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,\nand continued compliance with the NYSE’s other continued listing requirements.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","comparable_excerpt":"May 19, 2026, All In FutureTech Alliance,\nInc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)\nfrom the Listing Qualifications Department (the “Staff”) of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm"}},{"accession":"0001213900-26-060662","ticker":"TNON","company_name":"Tenon Medical, Inc.","filed_at":"2026-05-22T21:15:15+00:00","headline":"Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060662","json":"https://secwatch.observer/filing/0001213900-26-060662.json","markdown":"https://secwatch.observer/filing/0001213900-26-060662.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/ea0291962-8k_tenon.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will\nbe unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock\nremains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of\nthe NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,\nand continued compliance with the NYSE’s other continued listing requirements.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","comparable_excerpt":"May 21, 2026, Tenon Medical, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying\nthe Company that it is no longer in compliance with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm"}},{"accession":"0001213900-26-058167","ticker":"SNYR","company_name":"Synergy CHC Corp.","filed_at":"2026-05-18T13:01:37+00:00","headline":"Synergy CHC receives Nasdaq delisting notice for bid price below $1.00","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-058167","json":"https://secwatch.observer/filing/0001213900-26-058167.json","markdown":"https://secwatch.observer/filing/0001213900-26-058167.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/0001213900-26-058167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/ea0291276-8k_synergy.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will\nbe unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock\nremains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of\nthe NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,\nand continued compliance with the NYSE’s other continued listing requirements.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","comparable_excerpt":"May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of\nThe Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/0001213900-26-058167-index.htm"}},{"accession":"0001104659-26-057974","ticker":"HUMA","company_name":"Humacyte, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057974","json":"https://secwatch.observer/filing/0001104659-26-057974.json","markdown":"https://secwatch.observer/filing/0001104659-26-057974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/tm2614071d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will\nbe unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock\nremains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of\nthe NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,\nand continued compliance with the NYSE’s other continued listing requirements.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","comparable_excerpt":"May 4, 2026, Humacyte, Inc. (the “Company”)\nreceived a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification\nthat, for the 30 consecutive business days ended May 1, 2026, th","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm"}},{"accession":"0001213900-26-059270","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-05-20T12:49:08+00:00","headline":"Tether International acquires SoftBank's stake in Twenty One Capital; board members resign","event_type":"other_material","sec_items":["1.02","3.01","5.02","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-059270","json":"https://secwatch.observer/filing/0001213900-26-059270.json","markdown":"https://secwatch.observer/filing/0001213900-26-059270.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/ea0291071-8k_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will\nbe unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock\nremains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of\nthe NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,\nand continued compliance with the NYSE’s other continued listing requirements.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","comparable_excerpt":"o independent directors, the minimum number required during the transition period\nfor compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm"}},{"accession":"0001829126-26-004960","ticker":"PMI","company_name":"Picard Medical, Inc.","filed_at":"2026-05-11T21:08:14+00:00","headline":"Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity","event_type":"other_material","sec_items":["1.01","3.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 1.01, 3.01, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004960","json":"https://secwatch.observer/filing/0001829126-26-004960.json","markdown":"https://secwatch.observer/filing/0001829126-26-004960.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/picardmedical_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will\nbe unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock\nremains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of\nthe NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,\nand continued compliance with the NYSE’s other continued listing requirements.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm","comparable_excerpt":"May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}